434.31
-2.27 (-0.52%)
| Penutupan Terdahulu | 436.58 |
| Buka | 435.54 |
| Jumlah Dagangan | 1,219,096 |
| Purata Dagangan (3B) | 1,278,672 |
| Modal Pasaran | 110,230,233,088 |
| Harga / Pendapatan (P/E TTM) | 25.78 |
| Harga / Pendapatan (P/E Ke hadapan) | 22.62 |
| Harga / Jualan (P/S) | 9.05 |
| Harga / Buku (P/B) | 5.63 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 3 Aug 2026 |
| Margin Keuntungan | -8.91% |
| Margin Operasi (TTM) | 37.22% |
| EPS Cair (TTM) | -3.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 3.00% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -41.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 10.00% |
| Nisbah Semasa (MRQ) | 2.65 |
| Aliran Tunai Operasi (OCF TTM) | -980.30 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 2.63 B |
| Pulangan Atas Aset (ROA TTM) | 11.77% |
| Pulangan Atas Ekuiti (ROE TTM) | -5.64% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Vertex Pharmaceuticals Incorpor | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 1.30 |
|
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Large Value |
| % Dimiliki oleh Orang Dalam | 0.15% |
| % Dimiliki oleh Institusi | 97.64% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Loomis Sayles & Co L P | 31 Mar 2026 | 4,003,821 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 641.00 (HC Wainwright & Co., 47.59%) | Beli |
| Median | 596.00 (37.23%) | |
| Rendah | 525.00 (Truist Securities, 20.88%) | Beli |
| Purata | 589.29 (35.68%) | |
| Jumlah | 7 Beli | |
| Harga Purata @ Panggilan | 498.20 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Truist Securities | 11 Mar 2026 | 525.00 (20.88%) | Beli | 492.38 |
| B of A Securities | 10 Mar 2026 | 598.00 (37.69%) | Beli | 499.17 |
| Citigroup | 10 Mar 2026 | 585.00 (34.70%) | Beli | 499.17 |
| HC Wainwright & Co. | 10 Mar 2026 | 641.00 (47.59%) | Beli | 499.17 |
| Jefferies | 10 Mar 2026 | 580.00 (33.55%) | Beli | 499.17 |
| Morgan Stanley | 10 Mar 2026 | 596.00 (37.23%) | Beli | 499.17 |
| Oppenheimer | 10 Mar 2026 | 600.00 (38.15%) | Beli | 499.17 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BOZIC CARMEN | - | 442.62 | -8,342 | -3,724,281 |
| BUNNAGE MARK E. | - | 436.95 | -33 | -14,419 |
| Jumlah Keseluruhan Kuantiti Bersih | -8,375 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -3,738,700 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 440.73 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BOZIC CARMEN | Pegawai | 15 May 2026 | Jual automatik (-) | 1,354 | 436.95 | 591,630 |
| BUNNAGE MARK E. | Pegawai | 15 May 2026 | Jual automatik (-) | 33 | 436.95 | 14,419 |
| BOZIC CARMEN | Pegawai | 12 May 2026 | Jual automatik (-) | 6,988 | 448.29 | 3,132,651 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |